| Literature DB >> 26545368 |
Tracy A Larson1,2, Karin L Lent3, Theo K Bammler4, James W MacDonald4, William E Wood5,6,7, Melissa L Caras3,6,8, Nivretta M Thatra1,3, Agata Budzillo5,6, David J Perkel1,5, Eliot A Brenowitz9.
Abstract
BACKGROUND: Adult neurogenesis and the incorporation of adult-born neurons into functional circuits requires precise spatiotemporal coordination across molecular networks regulating a wide array of processes, including cell proliferation, apoptosis, neurotrophin signaling, and electrical activity. MicroRNAs (miRs) - short, non-coding RNA sequences that alter gene expression by post-transcriptional inhibition or degradation of mRNA sequences - may be involved in the global coordination of such diverse biological processes. To test the hypothesis that miRs related to adult neurogenesis and related cellular processes are functionally regulated in the nuclei of the avian song control circuit, we used microarray analyses to quantify changes in expression of miRs and predicted target mRNAs in the telencephalic nuclei HVC, the robust nucleus of arcopallium (RA), and the basal ganglia homologue Area X in breeding and nonbreeding Gambel's white-crowned sparrows (Zonotrichia leucophrys gambelli).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26545368 PMCID: PMC4636775 DOI: 10.1186/s12864-015-2175-z
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Experimental design. a A schematic of the song nuclei sampled for microarray analysis. The dotted line indicates where tissue samples were obtained. b Experimental time-line for all experimental groups. A red line indicates termination of the experiment for the given group. c Representative images of Nissl-stained brain sections confirming tissue punch locations in HVC, RA and Area X. The arrowheads indicate the borders of the respective nuclei as determined by cell morphology and density
Fig. 2Patterns of changing expression of mRNA and miR transcripts between breeding and nonbreeding conditions. Expression data were converted to z-scores for each mRNA or miR. Thus colors represent up (red) or down (blue) regulation of a miR or mRNA in a particular sample, as compared to the mean expression for that gene. a The relative expression of mRNAs that were differentially regulated in at least one experimental group (i.e. LD + T 3D, 7D, 21, or LDW) compared to SD. A p-value of <0.0001 and a fold change >2.0 were used as the threshold for inclusion. b Relative expression of miRs that were differentially regulated in at least one experimental group with a fold change >2.0 and p < 0.0005 compared to SD. miRs of interest based on predicted function or miRs specific to birds are denoted
Top canonical pathways of mRNAs seasonally regulated in HVC, RA, and Area X
| Top Canonical Pathways |
| Ratio | # of Genes | |
|---|---|---|---|---|
| HVC | ||||
| 3D | RAN Signaling | 0.0009 | 0.214 | 3 |
| Cell Cycle Control | 0.0235 | 0.118 | 2 | |
| 7D | Galactose Degradation | 0.0280 | 0.200 | 1 |
| UDP-N-acetyl-D-galactosamine Biosynthesis | 0.0057 | 0.143 | 1 | |
| 21D | ERK5 Signaling | 0.0001 | 0.103 | 4 |
| NGF Signaling | 0.0064 | 0.062 | 5 | |
| LDW | ATM Signaling | 0.0168 | 0.075 | 3 |
| Tumoricidal Function | 0.0171 | 0.133 | 2 | |
| RA | ||||
| 3D | Wnt/Ca + Pathway | 0.0500 | 0.214 | 1 |
| Axonal Guidance Signaling | 0.0500 | 0.008 | 2 | |
| 7D | Myo-inositol Signaling | 0.0081 | 0.086 | 3 |
| T Lymphcyte Signaling | 0.0478 | 0.042 | 1 | |
| 21D | Cancer Signaling | 0.0027 | 0.056 | 2 |
| Synaptic Long Term Depression | 0.0105 | 0.023 | 2 | |
| LDW | Sphingosine Metabolism | 0.0054 | 0.500 | 1 |
| Ceramide Degradation | 0.0054 | 0.500 | 1 | |
| Area X | ||||
| 3D | Galactose Degradation | 0.0152 | 0.200 | 1 |
| RAN Signaling | 0.0420 | 0.071 | 1 | |
| 7D | Flavin Biosynthesis | 0.0029 | 1.000 | 1 |
| Salvage Pathway | 0.0110 | 0.025 | 1 | |
| 21D | Granulocyte Adhesion | 0.0130 | 0.045 | 2 |
| Gylcerol Degradation | 0.0197 | 0.200 | 1 | |
| LDW | LPS/ IL-1 Mediated Function | 0.0060 | 0.056 | 5 |
| MIF-mediated Glucocorticoid Regulation | 0.0100 | 0.167 | 2 | |
Significantly differentially expressed miRNAs with a fold change >1.5 and p < 0.0005
| 3D | 7D | 21D | LDW | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HVC | miRNA | Fold Change |
| miRNA | Fold Change |
| miRNA | Fold Change |
| miRNA | Fold Change |
|
| miR-132 (4)a | 1.88 ± 0.18 | 0.0015 | miR-132 (12) | 2.83 ± 0.06 | 0.0033 | miR-132 (13) | 3.63 ± 0.07 | <0.0001 | miR-132 (13) | 3.65 ± 0.10 | 0.0001 | |
| miR-1356 | 2.00 | <0.0001 | miR-134 | −1.12 | 0.0001 | |||||||
| miR-212 | 1.96 | 0.0001 | miR-1182 | −1.81 | 0.0005 | |||||||
| miR-2840 | 1.69 | 0.0004 | miR-404 | −1.83 | 0.0005 | |||||||
| miR-1915 | −1.98 | 0.0002 | ||||||||||
| miR-395f | −2.11 | 0.0003 | ||||||||||
| miR-2455 | −2.23 | 0.0003 | ||||||||||
| miR-1562 | −2.39 | 0.0002 | ||||||||||
| miR-4516 | −2.44 | <0.0001 | ||||||||||
| miR-574 | −2.45 | 0.0005 | ||||||||||
| miR-295 | −2.53 | 0.0004 | ||||||||||
| miR-395b | −2.57 | 0.0001 | ||||||||||
| miR-1782 | −2.68 | 0.0004 | ||||||||||
| miR-1362 | −2.79 | 0.0001 | ||||||||||
| RA | ||||||||||||
| miR-281 | 4.47 | 0.0001 | miR-34a | 5.00 | <0.0001 | miR-132 (4) | 1.88 ± 0.05 | 0.0001 | miR-132 (4) | 1.90 ± 0.11 | 0.0001 | |
| miR-1192 | 3.98 | 0.0003 | miR-2111n | 4.84 | <0.0001 | miR-2525 | −2.40 | 0.0004 | ||||
| miR-184 | 3.94 | 0.0004 | miR-2571 | 4.47 | 0.0001 | |||||||
| miR-77 | 3.86 | 0.0005 | miR-311b | 4.29 | 0.0001 | |||||||
| miR-4197 | −3.92 | 0.0004 | miR-4142 | 4.02 | 0.0003 | |||||||
| miR-236 | −3.94 | 0.0004 | mir-135a | 3.98 | 0.0003 | |||||||
| miR-2182 | −4.03 | 0.0003 | miR-8 | 3.97 | 0.0003 | |||||||
| miR-758 | −4.04 | 0.0003 | miR-199b | 3.85 | 0.0005 | |||||||
| miR-982 | −4.33 | 0.0001 | miR-837 | −3.90 | 0.0004 | |||||||
| miR-34 | −4.62 | 0.0001 | miR-528 | −4.03 | 0.0003 | |||||||
| mir-4478 | −4.73 | <0.0001 | miR-441a | −4.15 | 0.0002 | |||||||
| miR-3479 | −5.23 | <0.0001 | miR-395 g | −4.17 | 0.0002 | |||||||
| mir-23a | −4.22 | 0.0002 | ||||||||||
| miR-2357 | −4.23 | 0.0002 | ||||||||||
| mir-3673 | −4.35 | 0.0001 | ||||||||||
| mir-129 | −4.64 | <0.0001 | ||||||||||
| Area X | ||||||||||||
| miR-2491 | 2.00 | 0.0002 | miR-210 | −1.96 | <0.0001 | miR-3751 | 1.35 | <0.0001 | miR-132 (6) | 1.69 ± 0.06 | 0.0002 | |
| miR-132 (2) | −1.79 ± 0.16 | 0.0002 | miR-210 (4) | −1.71 ± 0.09 | 0.0003 | miR-1713 | −1.55 | <0.0001 |
Fold changes are mean ± S.E.M. across all probes satisfying selection criteria, whereas p-value is that of the least significant result satisfying selection criteria
aNumber of probes with expression meeting selection criteria in parentheses
Fig. 3qRT-PCR validation miR microarray identification of miR-132 as differentially regulated between seasons. Fold change in expression of miR-132 from the microarray (M; shown in light colors) compared to qRT-PCR (P; dark colors). All fold-changes are relative to SD. miR-132 trended towards differential expression with qRT-PCR at LD + T 7D in HVC (adjusted-p = 0.0802) and achieved significant differential expression at LD + T 21D in RA (adjusted-p = 0.0427)
Fig. 4The seasonal miR-132–mRNA regulatory network in HVC. a The relative expression changes of mRNA targets of miR-132 that were differentially regulated in at least one experimental group (i.e. LD + T 3D, 21, or LDW) compared to SD, as well as having an inverse correlation to miR-132 in the same comparison. A p-value of <0.005 and a fold change >1.5 at any time point were used as selection criteria for mRNAs presented in the heat map. b An interaction network of mRNAs that were differentially anti-expressed with a fold change > -1.5 and p < 0.005 from conditions in which miR-132 was also differentially expressed (i.e. fold change > 2.0). IPA network analyses revealed several key pathways were down-regulated during periods of HVC new neuronal addition and functional incorporation
Top pathways for miR-132 and miR-210 predicted mRNA targets across all time points
| Top Canonical Pathway |
| Ratio | Genes | |
|---|---|---|---|---|
| miR-132 HVC | ||||
| Molecular Mechanisms of Cancer | <0.0001 | 0.0301 | E2F5, CFLAR, ADCY3, ARHGEF10, CDKN1A, MAPK1, TGFB2, PRKD1, RAP2B, PRKAG2, FOXO1 | |
| RAR Activation | 0.0001 | 0.0398 | ADCY3, MAPK1, TGFB2, PRKD1, PRKAG2, NCOR1, GTF2H1 | |
| VDR/RXR Activation | 0.0001 | 0.0641 | CDKN1A, TGFB2, PRKD1, NCOR1, FOXO1 | |
| Breast Cancer Regulation by Stathmin1 | 0.0001 | 0.0366 | E2F5, ADCY3, ARHGEF10, CDKN1A, MAPK1, PRKD1, PRKAG2 | |
| ErbB Signaling | 0.0001 | 0.0581 | HBEGF, MAPK1, PRKD1, NRG2, FOXO1 | |
| Pancreatic Adenocarcinoma Signaling | 0.0003 | 0.0472 | E2F5, HBEGF, CDKN1A, MAPK1, TGFB2 | |
| Cell Cycle: G1/S Checkpoint Regulation | 0.0005 | 0.0625 | E2F5, CDKN1A, TGFB2, FOXO1 | |
| PPARα/RXRα Activation | 0.0005 | 0.0335 | ADCY3, MAPK1, TGFB2, CAND1, PRKAG2, NCOR1 | |
| Leptin Signaling | 0.0008 | 0.0541 | ADCY3, MAPK1, PRKAG2, FOXO1 | |
| Acute Myeloid Leukemia Signaling | 0.0009 | 0.0519 | KITLG, MAPK1, TCF7L2, TCF7L1 | |
| miR-210 Area X | ||||
| Phospholipase C Signaling | 0.0022 | 0.0126 | ADCY5, BTK, PPP1CB | |
| Dopamine Receptor Signaling | 0.0033 | 0.0256 | ADCY5, PPP1CB | |
| CDK5 Signaling | 0.0052 | 0.0202 | ADCY5, PPP1CB | |
| NAD Biosynthesis III | 0.0066 | 0.1670 | NMNAT2 | |
| Phosphatidylcholine Biosynthesis I | 0.0078 | 0.1430 | PCYT1B | |
| NAD Salvage Pathway III | 0.0078 | 0.1430 | NMNAT2 | |
| Cellular Effects of Sildenafil (Viagra) | 0.0089 | 0.0155 | ADCY5, PPP1CB | |
| β-adrenergic Signaling | 0.0093 | 0.0150 | ADCY5, PPP1CB | |
| Calcium Transport I | 0.0100 | 0.1110 | ATP2B3 | |
| Dopamine-DARPP32 Feedback in cAMP Signaling | 0.0135 | 0.0124 | ADCY5, PPP1CB | |
Top pathways for miR-132 in HVC predicted mRNA targets at each time point
| Top Canonical Pathways |
| Ratio | # Genes | |
|---|---|---|---|---|
| LD + T 3D | ||||
| Breast Cancer Regulation | 0.0017 | 0.0209 | 4 | |
| Estrogen-mediated S-phase Entry | 0.0019 | 0.0833 | 2 | |
| Molecular Mechanisms of Cancer | 0.0028 | 0.0137 | 5 | |
| Cell Cycle Checkpoint Control | 0.0094 | 0.0364 | 2 | |
| Wnt/β-catenin Sginaling | 0.0103 | 0.0178 | 3 | |
| LD + T 7D | ||||
| PTEN Signaling | 0.0009 | 0.0254 | 3 | |
| AMPK Signaling | 0.0013 | 0.0224 | 3 | |
| Melanoma Signaling | 0.0030 | 0.0476 | 2 | |
| Calcium Signaling | 0.0029 | 0.0169 | 3 | |
| Antiproliferative Role | 0.0046 | 0.0317 | 2 | |
| LD + T 21D | ||||
| ErbB Signaling | <0.0001 | 0.0581 | 5 | |
| Neuregulin Signaling | 0.0001 | 0.0455 | 4 | |
| ErbB2/3 Signaling | 0.0006 | 0.0526 | 3 | |
| Molecular Mechanisms of Cancer | 0.0006 | 0.0164 | 6 | |
| ErbB4 Signaling | 0.0007 | 0.0500 | 3 | |
| LDW | ||||
| Melanocyte Development, Pigmentation Signaling | 0.0001 | 0.0357 | 3 | |
| CDK5 Signaling | 0.0002 | 0.0303 | 3 | |
| RAR Activation | 0.0009 | 0.0170 | 3 | |
| PPARα/RXRα Activation | 0.0010 | 0.0168 | 3 | |
| Pyridoxal 5’-phosphate Salvage Pathway | 0.0023 | 0.0313 | 2 | |
Fig. 5The seasonal miR-210 –mRNA regulatory network in HVC. a The expression fold changes of miR-210 mRNA that were differentially regulated and inversely correlated in at least one experimental group in which miR-210 was also differentially expressed (i.e. LD + T 7D, 21, or LDW) compared to SD. A p-value of <0.005 and fold change >1.5 at any time point were used as selection criteria for mRNAs presented in the heat map. b An interaction network of mRNAs that were differentially anti-expressed with a fold change > 1.5 and p < 0.005 (bright) or p < 0.05 (faded) from conditions in which miR-210 was also differentially expressed (i.e. fold change > –2.0). IPA network analyses revealed several key pathways were up-regulated in Area X during periods of volume expansion
Top pathways for miR-210 in Area X predicted mRNA targets at each time point
| Top Canonical Pathways |
| Ratio | # Genes | |
|---|---|---|---|---|
| LD + T 7D | ||||
| Phospholipase C Signaling | 0.0049 | 0.0084 | 2 | |
| B Lymphocyte Signaling | 0.0184 | 0.0244 | 1 | |
| Serotonin Receptor Signaling | 0.0197 | 0.0227 | 1 | |
| Primary Immunodeficiency Signaling | 0.0232 | 0.0192 | 1 | |
| GABA Receptor Signaling | 0.0299 | 0.0149 | 1 | |
| LD + T 21D | ||||
| Phosphatidylcholine Biosynthesis | 0.0039 | 0.1430 | 1 | |
| Calcium Transport I | 0.0050 | 0.1110 | 1 | |
| Choline Biosynthesis III | 0.0071 | 0.0769 | 1 | |
| RAN Signaling | 0.0093 | 0.0588 | 1 | |
| Chemokine Signaling | 0.0389 | 0.0141 | 1 | |
| LDW | ||||
| Phospholipase C Signaling | 0.0007 | 0.0126 | 3 | |
| Dopamine Receptor Signaling | 0.0015 | 0.0256 | 2 | |
| CDK5 Signaling | 0.0025 | 0.0202 | 2 | |
| Cellular Effects of Sildenafil | 0.0042 | 0.0155 | 2 | |
| Cardiac β-adrenergic Signaling | 0.0044 | 0.0150 | 2 | |